articleJournal of Clinical InvestigationApr 15, 2003Closed access

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

Mayo Clinic · Amgen (United States)

Indexed incrossrefdoaj

Abstract

Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab’s against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated…

Citation impact

693
total citations
FWCI
9.85
Percentile
100%
References
44
Citations per year

Authors

6

Topics & keywords

Keywords
  • RANKL
  • Endocrinology
  • Internal medicine
  • Bone resorption
  • Stromal cell
  • Osteoclast
  • Chemistry
  • Bone marrow
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding